Volume 2 Supplement 2

Abstracts of the 1st Immunotherapy of Cancer Conference (ITOC1)

Meeting abstracts

Edited by Heinz Zwierzina and Volkmar Nuesslar

Publication of this supplement was funded by the Biotherapy Development Association, a non-profit organisation. The Supplement Editors declare that they have no competing interests.

1st Immunotherapy of Cancer Conference (ITOC1). Go to conference site.

Munich, Germany12-14 March 2014

Page 1 of 2

S2. Therapeutic strategies based on overcoming immune resistance mechanisms within the melanoma tumour microenvironment

Authors: T Gajewski

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I1

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S5. Proffered paper: Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703: clinical and immunological predictive pretreatment factors of activity in the IMPACT trial

Authors: H Schmoll, BW Wittig, DA Arnold, JRK Riera-Knorrenschild, DN Nietsche, HK Kroening, FM Mayer, JA Andel, RZ Ziebermayr and WS Scheithauer

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I2

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S6. Proffered paper: Anti-tumour immunomodulatory activity of heat shock protein Hsp70 in therapy of malignant brain tumours: preclinical and clinical data

Authors: M Shevtsov, A Kim, W Khachatryan, A Pozdnyakov, I Romanova, I Guzhova and B Margulis

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I3

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S7. KEYNOTE LECTURE: Immunobiological properties of the human cancer stem cells

Authors: C Maccalli, EZ Elisabetta Zambon, FC Filippo Capocefalo and GP Giorgio Parmiani

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I4

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S9. Proffered paper: Identification of novel immune checkpoints as targets for cancer immunotherapy

Authors: G Cojocaru, G Rotman, O Levy, A Toporik, L Dassa, I Vaknin, S Sameah-Greenwald, I Barbiro, E Neria and Z Levine

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I5

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S35. Investigating the ICOS/ICOSL pathway as a target for combination therapy with anti-CTLA-4

Authors: P Sharma

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I6

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S38. Many reasons for combining immunotherapy with chemotherapy to enhance anti tumour response

Authors: A Dalgleish, D Fowler, A Gravett, R Allen and W Liu

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I7

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S41. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer

Authors: C Klein

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I8

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S43. Dendritic cell vaccination combined with CTLA4 blockade

Authors: K Thielemans and B Neyns

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I9

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S47. Tumour infiltrating lymphocytes - a predictive marker?

Authors: J Galon

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I10

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S48. Biomarker development for ipilimumab and prostate GVAX treatment

Authors: T de Gruijl, S Santegoets, A Stam, S Lougheed, K Jooss, N Sacks, T Harding, K Hege, W Gerritsen and A van den Eertwegh

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I11

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S50. Proffered paper: Complex tumour microenvironment screening platform captures biological responses of cancer therapeutics

Authors: H Layman, J Melrose, W Tang, N Brown, D Nguyen, A Melton, M Polokoff, E Berg and A O'Mahony

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I12

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S75. KEYNOTE LECTURE: Basic concept for the understanding of cancer mediated immune rejection

Authors: F Marincola and E Wang

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I13

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S76. Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes

Authors: I Svane, R Andersen and M Donia

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I14

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S77. Proffered paper: In vitro induced response patterns of antileukemic T-cells – characterization by combination of functional assays, spectratyping and next generation sequencing

Authors: S Reuther, P Krell, FR Schuster, C Grabrucker, A Liepert, T Kroell, HJ Kolb, A Borkhardt, R Buhmann and H Schmetzer

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I15

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S78. Proffered paper: High-affinity CD20-specific TCRs suitable for adoptive immunotherapy can be readily isolated from the allo-repertoire using reverse immunology

Authors: L Jahn, P Hombrink, C Hassan, MGD Kester, MP Schoonakker, JHF Falkenburg, P van Veelen and MHM Heemskerk

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I16

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S79. CAR strategies in solid tumours

Authors: C Rossig

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I17

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S80. Prolongation of T cell response by OX40 co-signalling CARS

Authors: H Abken

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I18

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S81. Proffered paper: A new PD1-CD28 chimeric receptor overcomes PD-1-mediated immunosuppression in adoptive T cell therapy

Authors: S Grassmann, P Peters, Y Zeng, J Schmollinger, S Endres and S Kobold

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I19

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S82. Proffered paper: In-vivo testing of PSMA-targeted T-cell immunotherapy for prostate cancer

Authors: Z Liu, SB Papa, J Morris and J Maher

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I20

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
S49. Clinical activity and development of biomarkers for an engineered anti PDL1 antibody MPDL3280A

Authors: E Cha

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):I21

Content type: Invited speaker presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P10. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T cell and B cell responses but improves clinical efficacy in a murine pancreatic carcinoma model

Authors: C Bauer, A Sterzik, F Bauernfeind, P Duewell, C Conrad, R Kiefl, S Endres, A Eigler, M Schnurr and M Dauer

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P1

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P11. Developing an immunotherapy strategy for the effective treatment of patients with Non Small Cell Lung Cancer (NSCLC): strategies to evaluate immunity in patients on clinical trials

Authors: M Neuberger, C Paustian, T Hilton, N Engel, S Reu, A Linder, R Huber, R Hatz and H Winter

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P2

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P12. Combination of radiotherapy and chemotherapy with dendritic cell immunotherapy in glioblastoma patients induces NK and NKT cell responses

Authors: S Pellegatta, M Eoli, MG Bruzzone, S Cuzzubbo, E Anghileri, C Antozzi, S Frigerio, B Pollo, EA Parati and G Finocchiaro

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P3

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P13. Intra-tumoral and surrogate immune responses in patients treated with the engineered anti-PD-L1 antibody (MPDL3280A)

Authors: M Kowanetz, MT Vu, J Wu, H Koeppen, H Kohrt, S Gettinger, C Cruz, M Denker, DS Chen and P Hegde

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P4

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P14. Cell-based gene delivery leverages conventional immunotherapy for cancer

Authors: C Günther and R Huss

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P5

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P15. A genetic mouse model to identify the role of the immune adapter protein MyD88 in colorectal cancer

Authors: A Holtorf, B Holzmann and KP Janssen

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P6

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P16. Differential susceptibility of human and mouse NK cells to malignant cell-induced abnormalities in autologous combinations: a potential mechanism for the NK cell-based immunotherapy efficacy

Authors: G Sconocchia, R Arriga, S Caratelli, A Coppola, GC Spagnoli, G Lanzilli, B Capuani, F Ferrelli, D Lauro and S Ferrone

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P7

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P17. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells

Authors: M Schnurr, A Steger, H Lohr, H Bourhis, S Endres and P Duewell

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P8

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P18. The tumour leukocyte infiltrate is the key predictor for therapeutic response to catumaxomab therapy

Authors: K Weiler, L Rava, M Jäger, I Funke, M Joka, KW Jauch and B Mayer

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P9

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P19. Immunomodulation of blasts in AML-patients (pts) with clinically approved response modifiers to improve anti leukaemic T-cell reactivity: an ex vivo simulation of the clinical situation

Authors: H Schmetzer, Z Stankova, D Deen, A Hirn, Y Vokac, T Kroell, R Buhmann, A Hausmann, C Schmid and J Tischer

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P10

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P20. Lack of T cell exhaustion in acute myeloid leukaemia

Authors: FM Schnorfeil, FS Lichtenegger, K Emmerig, M Schlüter, R Draenert, W Hiddemann and M Subklewe

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P11

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P21. NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention

Authors: P Prinz and E Noessner

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P12

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P22. Immunomodulation induced by resveratrol or genistein on proliferation and apoptosis of tumour colon cells

Authors: L Brasoveanu, C Hotnog, M Bostan, G Matei, D Hotnog, M Gruia and M Mihaila

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P13

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P23. Efficient ex vivo lysis of acute myeloid leukaemic (AML) cells mediated by triplebodies with dual-targeting capability in conjunction with natural killer cells as effectors

Authors: G Fey, TA Braciak, S Wildenhain, CC Roskopf, C Schiller, N Fenn, IA Schubert, U Jacob, KP Hopfner and FS Oduncu

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P14

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P24. Aviscumine enhances NK- cytotoxicity against tumor cells

Authors: G Gamerith, A Amann, B Schenk, T Auer, JM Huber, K Cima, H Lentzen, J Löffler-Ragg, H Zwierzina and W Hilbe

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P15

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic

Authors: K Lykopoulos, P Collins, M Hall, R Ehness, J Barth and J Louahed

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P16

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P26. Cancer associated fibroblasts contribute to the immune suppression of breast cancer by augmentation of the inflammatory products

Authors: L Langroudi, ZM Hasan, M Soleimani and SMM Hashemi

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P17

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients

Authors: S Eketorp Sylvan, J Lundin, M Ipek, M Palma, C Karlsson and L Hansson

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P18

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P28. Efficient CD19-positive leukaemia cell lysis mediated by a T cell-recruiting triple body a[19-3-19]

Authors: CC Roskopf, TA Braciak, C Schiller, S Wildenhain, N Fenn, U Jacob, GH Fey, KP Hopfner and FS Oduncu

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P19

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P29. T-cell responses to oncogenic Merkel cell polyomavirus proteins distinguish Merkel cell carcinoma patients from healthy donors

Authors: L Lyngaa, NW Pedersen, D Schrama, CA Thrue, D Ibrani, O Met, P thor Straten, P Nghiem, JC Becker and SR Hadrup

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P20

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P30. The use of HER2 receptors status as a prognostic index for estrogen receptor positive breast cancer patients

Authors: A Tawfeek

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P21

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P31. Genomic profiling and functional characterisation of a new myeloid cell type enriched in renal cell carcinoma

Authors: D Brech, M Irmler, T Straub, P Bruns, C Jaekel and E Noessner

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P22

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P32. High resolution mass spectrometry reveals the depth and diversity of HLA-I peptidomes

Authors: M Bassani-Sternberg, S Frankild and M Mann

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P23

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P33. NK-92 cellular immunotherapy as an alternative to donor derived peripheral blood NK cells

Authors: H Klingemann

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P24

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P51. Identification of prostate cancer-associated antigens by oxygen manipulation

Authors: T Ma, A Elkhattouti, F Kosari, RJ Karnes, JC Cheville, G Vasmatzis, S Vuk-Pavlovic and RC Gomez

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P25

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P52. A new pathway of tumour antigen loading of human dendritic cells via intercellular communication

Authors: G Penna, M Ciranna, F Saccheri, L Morelli, C Pozzi and M Rescigno

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P26

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P53. Effect of lymphodepletion and tumour on host and reconstituted regulatory T-cells in a model of murine melanoma

Authors: J Kovács, P Rose, RA Hatz, H Winter and NK van den Engel

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P27

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P54. Possible role of MDSC for the induction of tumour-specific T cells following LRAST

Authors: P Rose, JR Kovács, RA Hatz, H Winter and NK van den Engel

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P28

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF
P55. Dendritic cell vaccination for postremission therapy in AML

Authors: FS Lichtenegger, B Beck, I Bigalke, C Geiger, W Hiddemann, R Henschler, G Kvalheim, DJ Schendel and M Subklewe

Citation: Journal for ImmunoTherapy of Cancer 2014 2(Suppl 2):P29

Content type: Poster presentation

Published on: 12 March 2014
- View Full Text
- View PDF

Abstracts of the 1st Immunotherapy of Cancer Conference (ITOC1)

Meeting abstracts

Journal for ImmunoTherapy of Cancer